of vitreous, retina and macular disease. Ophthalmologists continue to be updated on the latest treatments for these conditions as the U.S. population continues to age, it is important that expenditures for ophthalmic procedures have become a billion dollar business and healthcare organizations are increasingly devoting resources for ophthalmologists. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessions. Our audience consists of ophthalmologists with an interest in the management of macular diseases, including age-related macular degeneration (AMD) and other macular diseases. New information is best disseminated through interactive lectures, discussions and question and answer sessio
Friday, January 16, 2009

12:30 - 1:00pm Registration
1:00 - 1:05pm Introduction
1:05 - 2:00pm Ocular Oncology
1:00 - 1:05pm Introduction
Harvey Lincoff, M.D.
Lawrence Yannuzzi, M.D.

1:05 - 2:00pm Ocular Oncology
Chaiman: William Tamura, M.D.
Moderator: Hermann Schubert, M.D.
Advances in Diabetic Pharmacotherapeutics
Michael Creeson, M.D.
READ 2 Trial - Ranibizumab for Treatment of DME
Dong Nguyen, M.D.
Treatment of Diabetic Macular Edema with Topical Macugen
Neil Bressler, M.D.
Ranibizumab Dose Comparison in the Treatment of DME
Phillip Rosenfeld, M.D.
Forteone for AMD: the DRCR
K. Bailey Freund, M.D.
Diabetic Retinopathy Progress After Network Results
Ursula Schmidt-Erfurth, M.D.
Ranibizumab for Inflammatory CRVO
David Brown, M.D.

2:30 - 3:30pm Dry AMD
Chaiman: Thomas Aaberg Sr., M.D.
Moderator: Mark Blumenkranz, M.D.
Therapeutic Monoclonal Antibodies and its Relevance?
K. Bailey Freund, M.D.
Therapeutic Intravitreal Levels of VEGF and Cytokines
Ursula Schmidt-Erfurth, M.D.
Trast and Extend
Carl Regillo, M.D.
VEGF Trap Eye: A New Option in AMD Treatment
Jeffrey Heier, M.D.
Combination Treatment for AMD: Peter Kavan, M.D.
Update on the Comparison of AMD Treatment Trials
Joseph Maguire, M.D.

3:30 - 4:30pm Coffee Break & Exhibits
4:00 - 5:00pm Neovascular AMD
Chaiman: Thomas Aaberg Sr., M.D.
Moderator: Mark Blumenkranz, M.D.
Therapeutic Monoclonal Antibodies and its Relevance?
K. Bailey Freund, M.D.
Therapeutic Intravitreal Levels of VEGF and Cytokines
Ursula Schmidt-Erfurth, M.D.
Trast and Extend
Carl Regillo, M.D.
VEGF Trap Eye: A New Option in AMD Treatment
Jeffrey Heier, M.D.
Combination Treatment for AMD: Peter Kavan, M.D.
Update on the Comparison of AMD Treatment Trials
Joseph Maguire, M.D.

4:30 - 5:30pm The Calcott and Paul J. Scholz Light-Moon International Lectureship
The Role of Retinal Pigment Epithelial Destruction in Retinal Disease
Alan Belf, M.D.

Saturday, January 17, 2009

7:00 - 7:15am Welcome: Jack Dodick, M.D.
Introduction: Harvey Lincoff, M.D.
Lawrence Yannuzzi, M.D.

7:15 - 8:15am Ophthalmic Technology
Chaiman: Professor Roberto-Mario Molinari
Moderator: D. Jackson Coleman, M.D.
Photoacoustic Imaging and Infrared Cocoyocamperasides
Rando Allikmets, M.D.
Ocular Ultrasound
Paul Chen, M.D.
New Perspectives in Fundus Autofluorescence
Frank Heiz, M.D.
Erythocyte Movement in the Capillaries
Robert Frenkel, Ph.D.
Drug Delivery
Cathy Ouzts, M.D.
Decoding Drug Delivery and Ocular Drug Delivery
William Miler, M.D.

8:15 - 9:45am OCT Imaging
Chaiman: Garrett Foster, M.D.
Moderator: Caroni Paulus, M.D.
Special Domain (OCT of Dry AMD)
Scott Hofer, M.D.
Automated Divergence Detection with Spectral Domain OCT
Vik Fisher, M.D.
Saccular Lesion of Diabetic Macular Edema
Cyntia Tobi, M.D.
Fundus and SD-OCT Imaging
Giovanni Spinelli, M.D.
Diabetic Macular Edema Phenotypes
Edith Justo, M.D.
Choroidal Imaging with OCT
Richard Spady, M.D.
OCT and Retinal Function
John Thompson, M.D.
Special Domain OCT Artifact
Glenn Jaffe, M.D.

9:45 - 10:15am Coffee Break & Exhibits

10:15 - 11:15am Medical Retina
Chaiman: Joseph Wells, M.D.
Moderator: Robert Murphy, M.D.
Management of Posterior Vitreous Detachment
Doug Alm, M.D.
Corey Onsrud, M.D.
Surgical Treatment of Central Serous Chorioretinopathy
Lee Inamp, M.D.

A Syndrome Reassembling ASPM IPSE in Older Patients
Mark Johnson, M.D.
New Concepts in Retinal Neurprotection
George Williams, M.D.
Endotheliomophosis After Intravitreal Injections
Gary Flynn, M.D.
Nosi, Camp, Vive King Yang
Joe Pindl, M.D.
Macular Amyloid Type II
Lawrence Yannuzzi, M.D.

11:15 - 12:30pm Retinal Vascular
Chaiman: William Tamura, M.D.
Moderator: Hermann Schubert, M.D.
Advances in Diabetic Pharmacotherapeutics
Michael Creeson, M.D.
READ 2 Trial - Ranibizumab for Treatment of DME
Dong Nguyen, M.D.
Treatment of Diabetic Macular Edema with Topical Macugen
Neil Bressler, M.D.
Ranibizumab Dose Comparison in the Treatment of DME
Phillip Rosenfeld, M.D.
Forteone for AMD: the DRCR
K. Bailey Freund, M.D.
Diabetic Retinopathy Progress After Network Results
Ursula Schmidt-Erfurth, M.D.
Ranibizumab for Inflammatory CRVO
David Brown, M.D.

12:30 - 1:30pm Lunch & Exhibits